{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T04:10:10Z","timestamp":1719720610012},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009568","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T15:54:31Z","timestamp":1514390071000},"page":"e9568","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"96","author":[{"given":"Satoshi","family":"Nishiwaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yachiyo","family":"Kuwatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Yuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-86-20210226","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/asheducation-2011.1.231","article-title":"Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"2011","author":"Fielding","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R2-86-20210226","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","article-title":"Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia","volume":"123","author":"Mizuta","year":"2014","journal-title":"Blood"},{"key":"R3-86-20210226","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1179\/1607845412Y.0000000052","article-title":"The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Zhang","year":"2013","journal-title":"Hematology"},{"key":"R4-86-20210226","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","article-title":"Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study","volume":"19","author":"Tanguy-Schmidt","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-86-20210226","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R6-86-20210226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3324\/haematol.2013.085811","article-title":"Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)","volume":"99","author":"Wetzler","year":"2014","journal-title":"Haematologica"},{"key":"R7-86-20210226","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"R8-86-20210226","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-86-20210226","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-86-20210226","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","article-title":"Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy","volume":"143","author":"Yanada","year":"2008","journal-title":"Br J Haematol"},{"key":"R11-86-20210226","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"R12-86-20210226","first-page":"3","article-title":"Monitoring and managing minimal residual disease in acute lymphoblastic leukemia.","volume":"290-","author":"Hoelzer","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R13-86-20210226","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/cncr.28598","article-title":"Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"120","author":"Jeha","year":"2014","journal-title":"Cancer"},{"key":"R14-86-20210226","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2012.164","article-title":"Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"26","author":"Lee","year":"2012","journal-title":"Leukemia"},{"key":"R15-86-20210226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph\u200a+\u200aALL: a study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R17-86-20210226","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02986620","article-title":"Pilot phase I\/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma","volume":"77","author":"Ogura","year":"2003","journal-title":"Int J Hematol"},{"key":"R18-86-20210226","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","article-title":"Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"99","author":"Oki","year":"2008","journal-title":"Cancer Sci"},{"key":"R19-86-20210226","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1532\/IJH97.06023","article-title":"Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma","volume":"84","author":"Han","year":"2006","journal-title":"Int J Hematol"},{"key":"R20-86-20210226","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"R21-86-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"R22-86-20210226","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R23-86-20210226","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-86-20210226","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jjco\/hyg013","article-title":"A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma","volume":"33","author":"Takeyama","year":"2003","journal-title":"Jpn J Clin Oncol"},{"key":"R25-86-20210226","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.bmt.1704413","article-title":"Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma","volume":"33","author":"Endo","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R26-86-20210226","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ejh.12843","article-title":"Modified-CVAD and modified-CBAD compared to high dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma","volume":"98","author":"Gettys","year":"2017","journal-title":"Eur J Haematol"},{"key":"R27-86-20210226","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2008-03-143115","article-title":"Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen","volume":"112","author":"Laport","year":"2008","journal-title":"Blood"},{"key":"R28-86-20210226","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbmt.2008.02.018","article-title":"Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia","volume":"14","author":"Shigematsu","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-86-20210226","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12185-011-0944-2","article-title":"Outcome of medium-dose VP-16\/CY\/TBI superior to CY\/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia","volume":"94","author":"Shigematsu","year":"2011","journal-title":"Int J Hematol"},{"key":"R30-86-20210226","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int Immunol"},{"key":"R31-86-20210226","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3324\/haematol.2013.085167","article-title":"A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction","volume":"98","author":"Shinohara","year":"2013","journal-title":"Haematologica"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T03:50:18Z","timestamp":1719719418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712290-00086"}},"subtitle":["A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study)"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009568","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}